The company's share price has risen 12% in the last two sessions on Nasdaq.
The strong momentum in Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA; TASE: TEVA) ahead of the publication of its second quarter financials continues. Sales of the company’s flagship ethical drug for treating multiple sclerosis, Copaxone, continue to boost the company’s revenue.
Teva announced this morning that global in-market sales of Copaxone totaled $353 million for the second quarter of 2006, 22% more than for the corresponding quarter of 2005. US sales in the second quarter of 2006 increased 19% over the second quarter of 2005 to $231 million, and sales outside the US, mainly in Europe, rose 26% over the second quarter of 2005 to $123 million.
Teva’s share rose 12% in the last two trading sessions Nasdaq.
Published by Globes [online], Israel business news - www.globes.co.il - on August 2, 2006
© Copyright of Globes Publisher Itonut (1983) Ltd. 2006